Marshall Gerstein Partners to Speak on Biosimilar, Antibody and Medical Device Patent Strategies

CHICAGO--()--Leading litigation partners from the intellectual property law firm Marshall, Gerstein & Borun LLP will speak on key patent topics related to protecting innovation in the life sciences space at American Conference Institute’s annual Advanced Summit on Life Sciences Patents and its annual Advanced Summit on Medical Device Patents taking place at the Doubletree Times Square in New York this week, February 23-25, 2016.

On Tuesday, February 23, IP litigation partner John R. Labbe will participate in a panel discussion, “The Year of the Biosimilar: Refining Current Life Sciences Patent Strategies and Formulating a Multi-Faceted Approach for Innovators and Biosimilars Manufacturers” at the Advanced Summit on Life Sciences Patents. Panelists will discuss multiple topics surrounding biosimilars, including strategies for the so-called “patent dance” and patent litigation under the Biologics Price Competition and Innovation Act. The panel will consider the differences between BPCIA and Hatch-Waxman litigation and address recent case law including the Federal Circuit’s decision in Amgen v. Sandoz.

On Wednesday, February 24, IP Litigation partner Matthew C. Nielsen will participate in a panel discussion, “Antibody Strategy Session: Satisfying the Written Description/Enablement Requirement in Light of Stricter § 112 Standardsat the Advanced Summit on Life Sciences Patents. Panelists will review topics such as supporting your patent claim and securing antibody coverage through adequate written description post-AbbVie v. Janssen, Novozymes, and Nautilus, and balancing the inherent tension between the need to demonstrate unpredictability (in overcoming obviousness rejections) and producing an adequate written description. For more information about this conference, click here.

On Thursday, February 25, IP litigation partner and medical device practice chair Julianne M. Hartzell will participate in a panel discussion, “Lessons Learned from the First Medical Device Patent IPRs” at the Advanced Summit on Medical Device Patents. Panelists will discuss topics surrounding the first medical patent IPRs, including AIA procedures; IPR amendment practice, procedure and strategy; best practices while appearing before the PTAB; preparing for the first medical device Post-Grant Review (PGR) challenges; and other strategic considerations, including better use of reexam procedures, parallel proceedings with District Courts, and seeking judicial review. For more information about the conference, click here.

About Marshall, Gerstein & Borun LLP

Marshall, Gerstein & Borun LLP is exclusively focused on intellectual property law. Nearly half of the Firm’s professionals have been in-house as general counsel, patent counsel, technology transfer managers, scientists, engineers, or consultants. The Firm’s professionals offer depth of talent and seasoned experience in devising and executing intellectual property strategy and comprehensive IP solutions. Chambers & Partners has ranked Marshall, Gerstein & Borun as “first-rate for litigation,” and “one of the best biotechnology practices in the entire country.” Corporate Counsel magazine lists the Firm as a “Go-To Law Firm of the Top 500 Companies” for intellectual property and litigation. The Firm is also ranked as a top intellectual property law firm by Managing IP, Fortune, Intellectual Property Today, and Intellectual Asset Management magazines. Learn more at www.marshallip.com and www.PTABWatch.com.

Contacts

Marshall, Gerstein & Borun LLP
Anna Behrman, 312-474-6300

Release Summary

Marshall Gerstein litigation partners will speak at ACI’s annual Advanced Summit on Life Sciences Patents and its annual Advanced Summit on Medical Device Patents, February 23-25, 2016.

Contacts

Marshall, Gerstein & Borun LLP
Anna Behrman, 312-474-6300